Jensen, C

Jordan, M

McCauley, J

Scantlebury, V

Shapiro, R

Starzl, TE

Vivas, C

English

PubMed

D-Scholarship@Pitt

FK 506 in the Management of Nephrotic Syndrome After Renal Transplantation J. McCauley, R. Shapiro, M. Jordan, V. Scantlebury, C. Vivas, C. Jensen, and T.E. Starzl N EPHROTIC syndrome developing after renal trans-plantation has many etiologies. Recurrent focal scle-rosing glomerulonephritis is' ane of the leading causes.! Other etiologies include: (1) transplant glomerulopathy; (2) chronic rejection; (3) de novo membranous glomerulone-phritis (ON); and (4) other recurrent glomerulonephropa-thies (membranoproliferative glomerulonephritis [MPGN] , systemic lupus erythematosus [SLE], diabetes, etc).2 The important treatment goals for these patients are to control the metabolic consequences of nephrotic syndrome and delay or prevent progression of renal failure. None of these diseases has been successfully treated after transplantation with the therapies conventionally used for native kidney ON. After a dramatic improvement in proteinuria in a patient with de novo focal segmental glomerulosclerosis (FSGS). we embarked on a limited pilot trial to determine if FK 506 might be helpful in managing these patients.3 Because this was a probing effort. no patient with post-transplant nephrotic syndrome was eliminated from con-sideration. This diverse group of histological lesions might reproduce the immunologic mediators of the primary dis-ease that developed in the patient's native kidneys or initiate a wholly different set of immune processes that result in a totally different form of GN.4 Posttransplant glomerulopathies may provide a unique opportunity to investigate the determinants of glomerular injury. PATIENTS AND METHODS From March 1990 until May 1992,24 patients with posttransplant nephrotic syndrome were converted from cyclosporine A (eyA) to FK 506. Approximately half the patients were initially trans-planted at the University of Pittsburgh; the remainder were referred to the University of Pittsburgh specifically for manage-ment of the nephrotic syndrome with FK 506. The criteria for entry into this study were serum creatinine (Ser) <6.0 and the presence of nephrotic range proteinuria. Baseline graft biopsies were performed in all cases. Immunosuppression Protocols All patients were receiving eyA and prednisone immunosuppres-sion; most also received imuran. eyA was stopped 24 hours or the evening prior (12 hours) to conversion if no rejection was noted on baseline biopsies. The initial conversion FK 506 dose was .3 mglkgld given in two divided doses. After approximately six patients, the dose of FK 506 was lowered to .2 mglkgld in divided doses. This reduction in dosage was primarily due to significant nephrotoxicity and other symptoms of excessive FK 506 therapy. The starting dose was later lowered to .15 mglkgld twice per day if rejection was absent at the time of conversion. If moderate rejection was present on pretreatment biopsies, a dose of .2 to .3 mglkgld given twice was used. One patient with moderate rejec-tion received intravenous solumedrol at the time of conversion. Imuran was discontinued in the first cases but continued in the most recent patients in an attempt to reduce the dose of FK 506 required and the accompanying nephrotoxicity. The prednisone dose was initially reduced by approximately one half at the time of conversion in the early cases. The prednisone dose is now continued unchanged unless rejection is detected on pretreatment biopsies. Patient Groups by Pretreatment Graft Biopsy Based upon pretreatment biopsies, patients were classified into four groups: (1) FSGS (10 patients); (2) recurrent lupus nephrop-athy (2 patients); (3) chronic rejection (II patients); (4) de novo membranous GN (I patient). One of the patients with FSGS had de novo FSGS; his native kidney disease was polycystic kidney disease. One patient with chronic rejection also had evidence for transplant glomerulopathy, but the latter was not felt to be the predominant lesion. Definition of Outcomes Patients were considered improved if 24-hour protein excretion was reduced by at least 50% and Ser was < 1.5 mg/dL greater than baseline values. Patients were considered to have failed therapy if 24-hour protein excretion had not declined by at least 50%. If Ser increased >2.0 mg/dL or was progressively increas-ing, patients were considered to have failed. Any patient requiring dialysis or retransplantation was considered to have failed. Dif-ferences between means were determin"d by Student's I test or analysis of variance when appropriate. RESULTS Our experience in converting renal transplant patients from CyA to FK 506 was encouraged by the clinical outcome of our first patient; his clinical course is illus-trated in Fig 1. This patient. with a history of polycystic kidney disease. developed de novo FSGS with significant mesangial proliferation and mild acute cellular rejection From the Transplantation Institute of the University of Pitts-burgh, Departments of Medicine and Surgery, Presbyterian-Uni-versity Hospital, and Veterans Affairs Medical Center, Pittsburgh, Pennsylvania. Address reprint requests to Jerry McCauley, MD. 709 Lhormer Building, Transplantation Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213. © 1993 by Appleton & Lange 0041-1345/93/$3.001 +0 Transplantation Proceedings, Vol 25, No 1 (February). 1993: pp 1351-1354 1351 --1352 McCAULEY, SHAPIRO, JORDAN ET AL 11.00 2.20 .... >-« 9.17 Q , en K"~ "'., " \ .. -, 1.76 -:Ii « 7.33 II: 0 --z 5.50 iii ¥ .. , .... .-..... • K~ ., -, ,., '&-,. ... Q -0 1.32 :Ii --ILl Z ~ 0 II: a. 3.87 II: ::J 0 :z: 1.83 "" CIt "-~~ ....... 0.00 z 0.88 j::: <I( ILl II: (J 0.44 0.00 Fig 1. Clinical course of the first patient treated converted from CyA to FK 506 for nephrotic syn-drome. -1 0 1 2 3 4 5 6 8 9 16 24 32 52 60646872 WEEKS -e- PROTEIN --.. - CREATININE (ACR) on a pretreatment biopsy. Simple conversion from Cy A to FK 506 resulted in a rapid and sustained fall in proteinuria without deterioration in renal function. These encouraging results led us to explore a potential role for this drug in managing nephrotic syndrome after renal transplantation. The clinical outcomes in all patients by pretreatment renal histology are illustrated in Fig 2. Twenty-four-hour protein excretions were: FSGS (7.2 ± 1.2 g pretreatment to 3.9 ± 2.9); recurrent SLE (5.4 ± 2.5 pre and 2.6 ± 2.4 post); and chronic rejection (8.5 ± 1.3 pre and 5.6 ± 1.9 post). There was no significant difference in pretreatment ~ ::::l o :z: "" N -en :::E <I( a: S!. z w ~ o a: a.. w z a: ::::l 15.00 12.50 10.00 7.50 5.00 2.50 0.00 FSGS or latest 24-hour protein excretion between groups al-though patient numbers were small. Only 1 of the 11 patients with FSGS was found to improve. 6 of 10 patients with FSGS. Neither of the two patients with SLE im-proved and the patient with de novo membranous GN has experienced a 50% fall in proteinuria after 2 months of therapy. The changes in renal function by pretreatment histology are demonstrated in Fig 3. Pretreatment and latest SCr were: FSGS (1.9 ± 0.2 to 1.8 ± 0.4 mgldL); SLE (1.85 ± 0.35 to 5.6 ± 2.4 mgldL); and chronic rejection (2.7 ± 0.4 to 5.5 ± 1.0 mg/dL). P < .05 FSGS pre and post vs chronic SLE CHRON REJ Fig 2. Urinary protein excretion by pretreatment allograft biopsy. Error bars are:!: SEM. _ PRE-FKS06 _ LATEST 2 .. I~ :rt· .-< MANAGING NEPHROTIC SYNDROME AFTER RENAL Tx 1353 9 8 ...... 7 ...J 0 - 8 0 ::E --w 5 z z 4 l-e( 3 w a: 0 2 1 0 FSGS SLE CHRON REJ Fig 3. Serum creatinine after conversion to FK 506. Error bars are:t SEM. _ PRE-FKS06 _ LATEST rejection. The 10 patients with chronic rejection have progressed to require dialysis or retransplantation. The sole patient with improved protein excretion died of a subarachnoid hemorrhage after 3 months of therapy. Both of the patients with SLE are awaiting retransplantation although neither has started dialysis to date. Four of the six patients with FSGS have been treated for approxi-mately 2 months. Two of the patients who failed had been converted after rapid recurrence of FSGS after transplan-tation. Institution of FK 506 therapy had no beneficial 11.00 ~ a: ::l 0 9.17 :I: ..,. C\I -en 7.33 :::Il e( a:: ~ 5.50 z w I- 3.87 0 a:: 0.. w 1.83 z a: ::l 0.00 effect on the patients' proteinuria and both ultimately required nephrectomy. The contribution of graft rejection on pretreatment bi-opsies to protein excretion is depicted in Fig 4. Patients with mild ACR experienced the greatest fall in protein excretion. Patients with moderate ACR or none had insig-nificant changes in proteinuria. Pretreatment and latest SCr by degree of rejection were: no ACR (2.54 ± 0.8 to 3.2 ± 1.0 mgldL); mild ACR (2.1 ± 0.26 to 3.7 ± 0.9 mgldL); and moderate ACR (2.6 ± 0.8 to 9.0 ± 1.0 mgldL). NONE MILD MODERATE Fig 4. Urinary protein excretion by degree of ACR on pretreat-ment allograft biopsies. Error bars are :t SEM. -PRE-FKS06 _ LATEST > ,j i, , . 1354 DISCUSSION Our growing experience with FK 506 in posttransplant nephrotic syndrome has revealed the limitations of this therapy and further defined the characteristics of the group of patients who are likely to benefit. Patients with chronic rejection of any degree on preconversion biopsies univer-sally fail to benefit and progress to end-stage renal disease or retransplantation. The presence of chronic rejection is probably an absolute contraindication for conversion to FK 506. These patients usually have advanced renal disease and apparently possess a nonimmunologic patho-physiological process that is irreversible. The speculated role of interleukin (IL)-l in this process may also explain the lack of effectiveness of an agent that is primarily an IL-2 inhibitor.5 Neither rapidly recurrent FSGS nor recur-rent SLE improved with FK 506. The lack of responsive-ness of these lesions is probably due to persistent immu-nologic factors, such as cytokine activation and persistent antibody production, that are not under the control of Cy A or FK 506. More encouraging results have been demonstrated in patients with de novo FSGS after transplantation. FSGS has been associated with increased IL-l, IL-2, and IL-8 production that may, at least in part. be inhibited by FK 506 in the early developmental stages. (HI Mild ACR as so-McCAULEY, SHAPIRO, JORDAN ET AL ciated with mesangial proliferation appears to be the most promising setting for FK 506 conversion. Interestingly, the absence of ACR or moderate ACR carried a worse prog-nosis. The use of FK 506 after renal transplantation is likely to be helpful in managing the nephrotic syndrome in a well-defined population of patients. Investigation of the deter-minants of responsiveness to FK 506 offers the opportu-nity to more fully uncover the causes of nephrotic syndrome both after transplantation and in native kidney glomerulonephritis. REFERENCES I. Senggutuvan p, Cameron IS, Hartley RB, et al: Pediat Nephrol4:21, 1990 2. Olassock RI, Adler SO, Ward HI, et al: In Brenner BM, Rector FC, (eds): The Kidney. 4th ed. Philadelphia, W.B. Saun-ders, 1991. p 1233 3, McCauley J. Shapiro R, Scantlebury V, et al: Transplant Proc 23:3354, 1991 4. Wardle EN: Nephron 257. 1991 5. Braun W: Conternp Issues Nephrol 19:45, 1989 6. Fukatsu A, Matsuo S. Tarnai H, et al: Lab Invest 65:61. 1991 7. Torbohm I, Berger B, Schoenermark M, et al: Clin Exp Immunol 75:427. 1989 8. Lovett DH, Larsen A: J Clin Invest 82: 115, 1988 a 

FK 506 in the management of nephrotic syndrome after renal transplantation

Name not available

http://d-scholarship.pitt.edu/4927/1/31735062113307.pdf

FK 506 in the management of nephrotic syndrome after renal transplantation

Abstract

Similar works

Full text

Available Versions

D-Scholarship@Pitt

Name not available

Name not available